CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...
Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...
An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step closer to producing a combined flu-and-Covid shot. But as scrutiny builds ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
The vaccine, called mRNA-1010, was tested in a Phase 3 study in adults ages 50 and older. It worked better than a standard-dose flu vaccine, providing 26.6% more protection against the flu overall, ...
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical ...
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback